Avantor, Inc. Aktie News

Brings more than three decades of leadership experience in the life sciences industry RADNOR, Pa. , Oct. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Gregory T.

RADNOR, Pa. , Oct. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, October 29, and will hold a conference call on the same day at 8:00 a.m.

Engine believes that Avantor's significant underperformance is a consequence of self-inflicted mistakes rooted in a flawed leadership team and framework.

Avantor surged Monday as Engine Capital digs in to reverse what the activist investor says are years of "extreme" value destruction.

Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to Begin Role as CEO Next Week RADNOR, Pa. , Aug. 11, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today issued the following statement in response to the letter...

Activist investor Engine Capital has urged medical equipment maker Avantor to refresh its board with new directors, a letter on Monday showed.

NEW YORK--(BUSINESS WIRE)--Engine Capital LP (together with its affiliates, “Engine” or “we”), which owns approximately 3% of the outstanding shares of Avantor, Inc. (NYSE: AVTR) (“Avantor” or the “Company”), today sent a letter to the Company's Board of Directors outlining several opportunities to close Avantor's significant valuation gap and unlock value for shareholders. The letter can be vi...

Activist investor Engine Capital has built a stake in Avantor and plans to push the life-sciences company to sell itself or make other changes, the Wall Street Journal reported on Sunday, citing people familiar with the matter.